Canakinumab as treatment for COVID-19-related pneumonia : A prospective case-control study
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia.
DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study: 33 patients (cases) signed informed consent and received canakinumab (Cohort 1) and 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (Cohort 2).
RESULTS: Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs. 26 days, respectively; p < 0.001). There was significant clinical improvement in ventilation regimes following administration of canakinumab compared with Cohort 2 (Stuart-Maxwell test for paired data, p < 0.001). Patients treated with canakinumab experienced a significant increase in PaO2:FiO2 (p < 0.001) and reduction in lung damage by CT (p = 0.01), along with significant decreases in immune/inflammation markers that were not observed in Cohort 2. Only mild side-effects were seen in patients treated with canakinumab; survival at 60 days was 90.0% (95% CI 71.9-96.7) in patients treated with canakinumab and 73.3% (95% CI 43.6-89.1) for Cohort 2.
CONCLUSIONS: Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favourable prognosis versus standard of care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:104 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 104(2021) vom: 01. März, Seite 433-440 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Generali, Daniele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37CQ2C7X93 |
|---|
| Anmerkungen: |
Date Completed 23.04.2021 Date Revised 10.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2020.12.073 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319496163 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319496163 | ||
| 003 | DE-627 | ||
| 005 | 20231225171551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.12.073 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319496163 | ||
| 035 | |a (NLM)33385581 | ||
| 035 | |a (PII)S1201-9712(20)32597-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Generali, Daniele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Canakinumab as treatment for COVID-19-related pneumonia |b A prospective case-control study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2021 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia | ||
| 520 | |a DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study: 33 patients (cases) signed informed consent and received canakinumab (Cohort 1) and 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (Cohort 2) | ||
| 520 | |a RESULTS: Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs. 26 days, respectively; p < 0.001). There was significant clinical improvement in ventilation regimes following administration of canakinumab compared with Cohort 2 (Stuart-Maxwell test for paired data, p < 0.001). Patients treated with canakinumab experienced a significant increase in PaO2:FiO2 (p < 0.001) and reduction in lung damage by CT (p = 0.01), along with significant decreases in immune/inflammation markers that were not observed in Cohort 2. Only mild side-effects were seen in patients treated with canakinumab; survival at 60 days was 90.0% (95% CI 71.9-96.7) in patients treated with canakinumab and 73.3% (95% CI 43.6-89.1) for Cohort 2 | ||
| 520 | |a CONCLUSIONS: Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favourable prognosis versus standard of care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Canakinumab | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a canakinumab |2 NLM | |
| 650 | 7 | |a 37CQ2C7X93 |2 NLM | |
| 700 | 1 | |a Bosio, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Malberti, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Cuzzoli, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Testa, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Romanini, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Fioravanti, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Morandini, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pianta, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Giannotti, Guglielmo |e verfasserin |4 aut | |
| 700 | 1 | |a Viola, Erika Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgi-Pierfranceschi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Foramitti, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Tira, Rosa Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Zangrandi, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Chiodelli, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Machiavelli, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cappelletti, Maria Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Giossi, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a De Giuli, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzi, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Campana, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Bernocchi, Ottavia |e verfasserin |4 aut | |
| 700 | 1 | |a Sirico, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Zoncada, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Molteni, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Venturini, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Giudici, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Scaltriti, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Angelo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 104(2021) vom: 01. März, Seite 433-440 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:104 |g year:2021 |g day:01 |g month:03 |g pages:433-440 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2020.12.073 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 104 |j 2021 |b 01 |c 03 |h 433-440 | ||